• 대한핵의학회지
• /
• 제36권1호
• /
• pp.19-27
• /
• 2002

The annual incidence of primary brain tumors is 7-19 cases per 100,000 people. The unique capacity of visualizing biochemical processes allows PET to determine functional metabolic activities of the brain tumors. Like other malignant tumors, F-18 FDG has been used commonly in the imaging of brain tumors. FDG PET is valuable in grading malignancy, predicting prognosis, monitoring treatment, differentiating tumor recurrence from radiation necrosis, and detecting primary lesion in metastatric brain tumors. Among amino acids labeled with positron emitters, C-11 methionine is used clinically. Tumor delineation is much better with methionine PET than with FDG PET. Low grade gliomas, in particular, are better evaluated with methionine than with FDG. PET opens another dimension in brain tumor imaging. PET imaging has clearly entered the clinical area with a profound impact on patient care in many indications.

• 대한의용생체공학회:의공학회지
• /
• 제35권3호
• /
• pp.68-74
• /
• 2014

Recent research on mild cognitive impairment (MCI) has shown that cognitive and memory decline in this disease is accompanied by disruptive changes in the brain functional network. However, there have been no graph-theoretical studies using $^{11}C$-PIB PET data of the Alzheimer's Disease or mild cognitive impairment. In this study, we acquired $^{18}F$-FDG PET and $^{11}C$-PIB PET images of twenty-four normal aging control participants and thirty individuals with MCI from ADNI (Alzheimer's Disease Neuroimaging Initiative) database. Brain networks were constructed by thresholding binary correlation matrices using graph theoretical approaches. Both normal control and MCI group showed small-world property in $^{11}C$-PIB PET images as well as $^{18}F$-FDG PET images. $^{11}C$-PIB PET images showed significant difference between NC (normal control) and MCI over large range of sparsity values. This result will enable us to further analyze the brain using established graph-theoretical approaches for $^{11}C$-PIB PET images.

• Bulletin of the Korean Chemical Society
• /
• 제29권1호
• /
• pp.61-68
• /
• 2008

High initial (2 minutes after iv injection) brain-uptake of PET agents is required to deliver the agent to binding sites in brain tissue but, for quantification of the specific binding, relatively rapid washout of free and non-specifically bound PET agents from the brain (30 minutes after injection) also is required. In order to compare the physicochemical properties of the PET agents which are responsible for early brain-uptake and rapid washout, respectively, chemometric analysis on brain-uptake of PET agents was performed via a classical VolSurf approach. According to the PCA and PLS results, high 2-30 min brain-uptake ratio seems to be related to the large hydrophobic regions in the PET agents which are not confined to a particular surface.

• 한국의학물리학회:학술대회논문집
• /
• 한국의학물리학회 2002년도 Proceedings
• /
• pp.322-323
• /
• 2002

Partial volume averaging effect of PET data influences on the accuracy of quantitative measurements of regional brain metabolism because spatial resolution of PET is limited. The purpose of this study was to evaluate the accuracy of partial volume correction carried out on $^{18}$ F-PET images using Hoffman brain phantom. $^{18}$ F-PET Hoffman phantom images were co-registered to MR slices of the same phantom. All the MR slices of the phantom were then segmented to be binary images. Each of these binary images was convolved in 2 dimensions with the spatial resolution of the PET. The original PET images were then divided by the smoothed binary images in slice-by-slice, voxel-by-voxel basis resulting in larger PET image volume in size. This enlarged partial volume corrected PET image volume was multiplied by original binary image volume to exclude extracortical region. The evaluation of partial volume corrected PET image volume was performed by region of interests (ROI) analysis applying ROIs, which were drawn on cortical regions of the original MR image slices, to corrected and original PET image volume. From the ROI analysis, range of regional mean values increases of partial volume corrected PET images was 4 to 14%, and average increase for all the ROIs was about 10% in this phantom study. Hoffman brain phantom study was useful for the objective evaluation of the partial volume correction method. This MR-based correction method would be applicable to patients in the. quantitative analysis of FDG-PET studies.

• Nuclear Medicine and Molecular Imaging
• /
• 제43권5호
• /
• pp.505-507
• /
• 2009

A 60-year-old woman, who had non-small-cell lung cancer (NSCLC) in left lower lobe underwent brain F-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for evaluation of cerebral metastasis. On follow-up FDG-PET/CT, only hypometaolic lesion was detected and progressed in right frontal lobe at 6 months and 10 months, later. Hypermetabolic metastasis was not detected even at last scan time of FDG-PET/CT. Brain MRI showed brain metastasis in right frontal lobe. As might be expected, the physician should take cerebral metastasis into consideration even though there is only hypometabolic change on subsequent FDG-PET/CT in patients with NSCLC.

• 핵의학기술
• /
• 제23권1호
• /
• pp.69-74
• /
• 2019

$^{18}F$-FDOPA는 뇌 종양의 아미노산 대사를 추적하는 방사성 의약품이다. 본 연구의 목적은 뇌 종양의 아미노산 대사를 영상화 하여 악성 종양을 진단하는 $^{18}F$-FDOPA와 포도당 대사를 통한 $^{18}F$-FDG의 Brain PET/CT 검사 영상의 대조도 분석을 통해 병변의 검출 능력을 비교하고, $^{18}F$-FDOPA Brain PET/CT 검사에서 섭취 시간에 따른 SUV의 변화를 분석하여 최적의 영상 획득 시간을 알아보기 위함이다. $^{18}F$-FDOPA 와 $^{18}F$-FDG 두 영상에서 종양(Tumor)과 소뇌(Cerebellum)의 중심에 각각 약 $350mm^2$의 관심 영역을 설정하여 $SUV_{max}$를 측정하였고, 종양과 소뇌의 $SUV_{max}$ 비율(T/C ratio)을 산출하였고, $^{18}F$-FDOPA 투여 직후 30분 동안 획득한 리스트 수집 방식 데이터(List mode data)를 활용해 2분씩 15프레임으로 나눈 뒤 각 프레임 별로 종양과 소뇌 중심에 $SUV_{max}$를 측정하여 위와 동일한 방법으로 T/C ratio를 산출하여 분석하였다. 종양의 평균 $SUV_{max}$를 비교해 본 결과, $^{18}F$-FDOPA Brain PET/CT 검사에서 $4.2{\pm}0.8$, $^{18}F$-FDG Brain PET/CT 검사에서는 $5.6{\pm}0.7$ 이었다. 또한, T/C ratio는 $^{18}F$-FDOPA 검사에서 $2.1{\pm}0.7$, $^{18}F$-FDG 검사에서는 $1.1{\pm}0.4$ 이었으며, $^{18}F$-FDOPA의 $SUV_{max}$는 $^{18}F$-FDG보다 낮지만 T/C ratio는 높게 나타나 종양 구별 능력이 더욱 뛰어난 것을 알 수 있었다(t=-5.214, p=0.000). $^{18}F$-FDOPA의 섭취 시간에 따른 $SUV_{max}$와 T/C ratio를 분석한 결과, $SUV_{max}$와 T/C ratio의 Peak는 모두 6~8분에서 나타났다. 이를 토대로 본원에서 $^{18}F$-FDOPA Brain PET/CT 검사에서 활용하는 10~30분의 영상과 Peak가 나타나기 시작한 6~26분의 영상을 비교한 결과 SUV와 T/C ratio가 각각 0.2, 0.1 증가하였다. 추후 지속적인 연구를 통해 검사 소요시간의 단축 가능성과 추가적인 스캔 정보 활용을 통한 정확한 진단에도 도움이 될 것으로 사료된다.

• 핵의학기술
• /
• 제19권2호
• /
• pp.68-73
• /
• 2015

PET/CT 검사 시 검사 부위에 따라 적절한 액세서리의 사용이 권고되고 있다. 그 중 brain 검사에서 사용되는 액세서리인 brain holder를 사용하지 않는 경우 CT의 small FOV에 의하여 whole pallet이 AC-CT에 cover되지 않으며, 이에 따른 truncated region에 따라 count loss가 발생된다. 본 논문에서는 brain holder를 사용하지 않았을 경우 발생하는 truncated region에 의한 image quality의 변화를 평가하고자 한다. Siemens사의 biograph truepoint40 장비와 $^{68}Ge$-uniform phantom을 사용하여 $^{68}Ge$ phantom을 pallet위에서 스캔하고 brain holder위에 위치하고 스캔 하였다. brain protocol을 적용하여 holder를 사용하지 않은 경우 pallet이 AC-CT의 FOV에 포함되지 않는 것을 알 수 있었다. 획득된 영상을 FBP, OSEM, TrueX recon method를 이용하여 iteration 4, subsets 21, gaussian 2 mm와 5 mm parameter를 적용하여 재구성 후 Window level : -4200, window width : 1000으로 설정하여 영상의 uniformity를 평가하였으며, vertical profile을 생성하여 count uniformity를 평가하였고, 마지막으로 5장과 20장의 slice를 summation하여 integral uniformity를 평가하였다. AC-CT영상을 통하여 holder를 사용하지 않는 경우 FOV내에 pallet이 모두 포함되지 않는 것을 알 수 있으며, 이에 따른 truncation에 의한 부정확한 attenuation factor가 나타났다 PET corrected sinogram 영상에서 holder를 사용하지 않은 경우 truncated region에 의한 defect 부위를 확인할 수 있으며, holder를 사용한 경우 uniform한 영상을 확인할 수 있었다. Window level : 4200, window width : 1000으로 설정 시 FBP, OSEM, TrueX recon 방법 모두에서 holder를 사용한 경우 uniform한 영상이 획득되었지만, holder를 사용하지 않은 경우 하단에 defect가 관찰되었다. Holder를 사용한 경우와 사용하지 않은 경우의 영상을 각 5장, 20장씩 summation하여 NEMA method에 따라 integral uniformity를 구하였으며, 5장 slice의 summation에서 holder를 사용하지 않은 경우 11.7% holder를 사용한 경우 7.2%로 나타났다. 20장 slice의 summation에서 holder를 사용하지 않은 경우 11.1% holder를 사용한 경우 76.7%로 나타났다. brain 검사 시 holder를 사용하지 않는 경우 truncated region에 따른 phantom 하단부의 count defect가 확인되었으며, 이는 환자 검사 시 occipital lobe의 count loss를 발생하게 되며 research 검사 시 검사 결과의 오차를 발생하게 됨으로 brain PET/CT 검사 시 정확한 검사결과를 위하여 검사 액세서리가 반드시 적용되어야 할 것이다.

• Brain Tumor Research and Treatment
• /
• 제6권2호
• /
• pp.47-53
• /
• 2018

Brain tumors represent a diverse spectrum of histology, biology, prognosis, and treatment options. Although MRI remains the gold standard for morphological tumor characterization, positron emission tomography (PET) can play a critical role in evaluating disease status. This article focuses on the use of PET with radiolabeled glucose and amino acid analogs to aid in the diagnosis of tumors and differentiate between recurrent tumors and radiation necrosis. The most widely used tracer is $^{18}F$-fluorodeoxyglucose (FDG). Although the intensity of FDG uptake is clearly associated with tumor grade, the exact role of FDG PET imaging remains debatable. Additionally, high uptake of FDG in normal grey matter limits its use in some low-grade tumors that may not be visualized. Because of their potential to overcome the limitation of FDG PET of brain tumors, $^{11}C$-methionine and $^{18}F$-3,4-dihydroxyphenylalanine (FDOPA) have been proposed. Low accumulation of amino acid tracers in normal brains allows the detection of low-grade gliomas and facilitates more precise tumor delineation. These amino acid tracers have higher sensitivity and specificity for detecting brain tumors and differentiating recurrent tumors from post-therapeutic changes. FDG and amino acid tracers may be complementary, and both may be required for assessment of an individual patient. Additional tracers for brain tumor imaging are currently under development. Combinations of different tracers might provide more in-depth information about tumor characteristics, and current limitations may thus be overcome in the near future. PET with various tracers including FDG, $^{11}C$-methionine, and FDOPA has improved the management of patients with brain tumors. To evaluate the exact value of PET, however, additional prospective large sample studies are needed.

• Nuclear Medicine and Molecular Imaging
• /
• 제42권sup1호
• /
• pp.1-5
• /
• 2008

Primary brain tumor accounts for 1.4% of entire cancer. For males between the ages of 15 and 34 years, central nervous system tumors account for the leading cause of cancer death. $^{18}F-FDG$ PET has been reported that it can provide important diagnostic information relating to tumor grading and differentiation from non- tumorous condition. In addition, the degree of FDG metabolism carries prognostic significance. By mapping the metabolic pattern of heterogeneous tumors, $^{18}F-FDG$ PET can aid in targeting for stereotactic biopsy by selecting the subregions within the tumor that are most hypermetabolic and potentially have the highest grade. According to clinical research data, FOG PET is expected to be a helpful diagnostic tool in the management of brain tumors.

• Journal of Genetic Medicine
• /
• 제9권2호
• /
• pp.84-88
• /
• 2012

Purpose: Neurofibromatosis type 1 (NF1), which is caused by mutations of the NF1 gene, is the most frequent single gene disorder to affect the nervous system. Unidentified bright objects (UBOs) are commonly observed on brain magnetic resonance imaging (MRI) in patients with NF1. However, their clinical and pathologic significance is not well understood. The purpose of this study was to investigate the correlation between UBOs and cerebral glucose metabolism measured by $^{18}F$-2-Fluoro-2-deoxy-D-glucose ($^{18}F$-FDG) positron emission tomography (PET) in Korean patients with NF1. Materials and Methods: Medical records of 75 patients (34 males and 41 females) with NF1 who underwent brain MRI and PET between 2005 and 2011 were evaluated retrospectively. Clinical data including demographics, neurological symptoms, and brain MRI and PET findings, were reviewed. Results: UBOs were detected in the brain MRI scans of 31 patients (41%). The region most frequently affected by UBOs was the basal ganglia. The most frequent brain PET finding was thalamic glucose hypometabolism (45/75, 60%). Of the 31 patients with UBOs, 26 had thalamic glucose hypometabolism on brain PET, but the other 5 had normal brain PET findings. Conversely, of the 45 patients with thalamic glucose hypometabolism on brain PET, 26 showed UBOs on their brain MRI scans, but 19 had normal findings on brain MRI scans. Conclusion: UBOs on brain MRI scans and thalamic glucose hypometabolism on PET appear to be 2 distinctive features of NF1 rather than correlated symptoms. Because the clinical significance of these abnormal imaging findings remains unclear, a longitudinal follow-up study of changes in clinical manifestations and imaging findings is necessary.